News Hub | News Direct

Monkeypox Is Popping Up In Places It Shouldn’t But NanoViricides Says It May Have A Solution

NanoViricides, Inc.

https://profiles.smallcapsdaily.com/nnvc/ More than 30,000 confirmed or suspected cases of monkeypox have been reported across 93 countries in the world. While those numbers are still small scientists are now concerned that this sudden and unusual outbreak could lead to monkeypox becoming endemic in these large numbers of new countries where it was only seen sporadically before. With no specific treatment approved for the virus, doctors are turning to old smallpox medications — a disease that hasn’t had a reported case in nearly 50 years — and off-label use of an antiviral approved for smallpox that was developed as a medical countermeasure for potential bioterrorism, SIGA Technologies Inc. ’s (NASDAQ: SIGA) TPOXX. TPOXX has a number of shortcomings. Its injectable form requires each dosing to be infused over 6 hours, twice daily for several days. The injectable form may be considered rapid-acting, for severe cases, but cannot be given to patients with renal impairment (kidney damage). However, there is an oral capsule form. In terms of mechanism, TPOXX inhibits orderly exit of a mature virion. However, most of the monkeypox virus particles exit due to cell lysis, and are infectious even though not fully mature; this mode is not affected by TPOXX. Most importantly, its utility in humans has not been established, as it was approved under the “Animal Rule” authority of the US FDA. It had shown effectiveness in monkeys to increase survival upon monkeypox virus infection. Importantly, TPOXX, during its development, has been known to give rise to resistant viruses or escape mutants. Something that scientists fear can give rise to new monkeypox viruses that may be worse than the current ones, as has been happening with the SARS-CoV-2 virus of COVID-19. Thus there is a clear and immediate need for rapid new drug development against monkeypox virus and potential variants. NanoViricides Inc. (NYSE American: NNVC ) reports that it may have a solution that would offer a more targeted treatment for the monkeypox virus that the virus may not escape from by mutations. The Strange And Sudden Outbreak Of Monkeypox What’s unusual about the outbreak is that although the “Patient Zero” in UK was connected to travel to Nigeria, and initial outbreaks occurred connected to raves in Europe, cases preceding to this outbreak have also been found to have occurred earlier, and not all the cases are linked to individuals who traveled to countries where the virus is usually found or have known contact with infected animals. While researchers are still trying to understand how that’s possible, the worry is that it’s been spreading silently and undetected for some time. And it can spread silently because an infected person is contagious even before the classic rash is present. The current outbreak also has different symptoms. Usually, a fever and swollen lymph nodes would precede the classic monkeypox rash and ulcers. However, with this virus, it appears that the rash can occur simultaneously with fever and swollen lymph nodes, or fever may even be absent. This is why possibly the rash of this virus was mistaken to be from other viruses such as herpes or shingles, although the monkeypox rashes behave distinctly differently from herpes or shingles rashes once formed. The Spread May Indicate Decreasing Immunity To Pox Viruses The monkeypox virus is a member of the poxviridae family along with smallpox, molluscum contagiosum and a few others. During the smallpox eradication program in the late 1960s, the vaccine used to prevent smallpox also helped curb monkeypox infections. Since 1980, smallpox has been declared to be entirely eradicated worldwide with successful worldwide vaccination campaigns. Smallpox does not have any animal reservoirs, it infects only humans, which contributed to its elimination. Monkeypox outbreaks have been regular in the endemic regions of Western and Central Africa, with annually thousands of cases. Many of these cases are deemed to be tied to transmission from animals rather than human to human transmission. But the recent uptick outside these regions may be related to the fact that many people born after the smallpox programs of the 60s stopped in 1980 have never had the smallpox vaccine. Even in those who received the smallpox vaccine, it has been over forty to sixty years, and the vaccine was expected to be effective for fifteen to twenty years only. With the last natural reported case of smallpox occurring in 1977, smallpox vaccines were seen as no longer necessary and widespread vaccination campaigns disappeared. While smallpox hasn’t come back, that decline in vaccination rates slowly brewed a generation of people who could be more vulnerable to other pox viruses in the family. The NanoViricides Platform May Offer A Rapidly Deployable Solution NanoViricides is a developmental-stage company working on an antiviral platform that a virus theoretically can’t outsmart. By chemically attaching a binding ligand to a nano-sized polymer, the company has created an antiviral that can attach to a virus’s binding site, which doesn’t mutate even as a virus evolves and looks similar across most viruses. Once attached, the nanoviricide engulfs the viral cell, blocking it from reproducing or infecting healthy cells. The company states that the broad-spectrum antiviral can be tailored to a wide range of viruses with the goal of providing a treatment that remains effective against just about any species and strain of virus that threatens the human population. With clinical candidates for COVID-19 and Shingles having successfully completed the full battery of IND-enabling studies, and preclinical research underway for a pipeline of additional treatments tailored to Herpesviruses, HIV, and more, the company has already found ways to adapt the platform to a broad range of difficult to treat viral infections. The company hopes to tailor an antiviral based on this platform to the recent and worrying resurgence of monkeypox cases. The Company has recently announced in its press releases that it is about to begin testing on its drug candidates for monkeypox virus treatment. The Company also said that it is following a two-pronged strategy: (a) The first one being to develop a quick drug to deploy rapidly that improves upon the existing drug tecovirimat so that it can be used widely including in patients that TPOXX is contraindicated; and (b) The second one being continued development of highly effective drugs against poxviruses and other DNA viruses that can add a strong drug to the current one-drug repertoire of poxvirus treatments. About NanoViricides NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. In addition, we are developing a clinical candidate for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. The Company cannot project an exact date for filing an IND for this drug because of its dependence on a number of external collaborators and consultants.The Company is now working on tasks for completing an IND application. The Company is currently pursuing two separate drug candidates for the treatment of COVID-19 patients. NV-CoV-2 is our nanoviricide drug candidate that does not encapsulate Remdesivir. NV-CoV-2-R is our other drug candidate that is made up of NV-CoV-2 with Remdesivir encapsulated in it. The Company believes that since Remdesivir is already US FDA approved, our drug candidate encapsulating Remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.The Company intends to re-engage into an IND application to the US FDA for NV-HHV-101 drug candidate for the treatment of shingles once its COVID-19 project moves into clinical trials, based on resources availability. The NV-HHV-101 program was slowed down because of the effects of recent COVID-19 restrictions, and re-prioritization for COVID-19 drug development work.The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for poxviruses if the initial research is successful. The Company's technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Contact Details NanoViricides, Inc. +1 203-937-6137 info@nanoviricides.com TraDigital IR Colette Eymontt colette@tradigitalir.com Company Website http://www.nanoviricides.com

August 10, 2022 08:00 AM Eastern Daylight Time

Cortland Biomedical Announces Suite of Post-Processing Services and Technologies for Implantable Textiles

Cortland Biomedical

Cortland Biomedical, a full-service medical textiles product development partner that provides access to a full spectrum of global engineering, design and manufacturing capabilities, today announced that it has added a suite of post-processing services and technologies. Offered in conjunction with its extensive range of knitting, weaving, and braiding capabilities, the latest services will enable the company to provide its OEM customers with their implantable fabric or device in its final form. Cortland Biomedical is adept at working with customers to develop complex, customized textile structures with highly tailored mechanical properties. Its suite of post-processing capabilities now includes: Spin Finish Removal, which can improve the biocompatibility of implantable fibers in any textile construction. Edge Sealing, which is performed by using a variety of proprietary methods to apply heat and/or weld materials to minimize loose fibers and/or fraying without impacting the base material. Ultrasonic Welding, which can benefit implantable fabrics via the highly precise application of heat to create complex shapes via the attachments of components, etc. Heat Pressing, which provides the ability to further specialize and alter braided, woven, and knit textiles to stabilize and improve their performance. Shape Setting and Thermal Forming, which are processes that are employed to set a fabric into a specific and often complex geometry to suit a specific surgical application. Braid Tipping, which ensures that braided products are manufactured for optimal performance by stiffening the ends to reduce fraying. Laser cutting, which provides almost endless possibilities for the design and manufacturing of smaller components. “Our mission has always been to overcome the status quo when it comes to helping our customers develop innovative, sophisticated, customized textiles that may ultimately enable less invasive surgical procedures,” said Tara Yunkunis, business development manager, Cortland Biomedical. “Now, by offering this comprehensive suite of post-processing capabilities, we’ll be able to further help streamline product delivery and minimize the need for additional suppliers.” All services are performed at Cortland Biomedical’s state-of-the-art 35,000 sq. ft. manufacturing facility, which was strategically designed for purpose with input from medical device partners and seasoned textile engineers. Cortland Biomedical custom designs and manufactures high-performance biomedical textile structures leveraging years of experience in medical textile engineering methods including knitting, braiding and weaving. Its thoughtful design concepts challenge the status quo. Cortland Biomedical’s unique combination of advanced equipment and technology, a seasoned medical textile-specific engineering team, and first-rate R&D capabilities allows it to tackle customers’ complex challenges with the innovation and agility expected in the medical device industry. Learn more at cortlandbiomedical.com. Contact Details Jordan Bouclin, SVM Public Relations +1 401-490-9700 Jordan.bouclin@svmpr.com Company Website https://www.cortlandbiomedical.com/

August 09, 2022 10:05 AM Eastern Daylight Time

Kadimastem Receives US Patent For Amyotrophic Lateral Sclerosis (ALS) Treatment

Kadimastem

Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing treatments for ALS and diabetes, has been granted a patent from the United States Patent and Trademark Office for its cell therapy technology for treating ALS and other neurodegenerative diseases. This US patent joins additional patents granted to Kadimastem in the US, Israel and Europe for the treatment of ALS and for ALS drug screening. Kadimastem’s flagship product, AstroRx®, is a breakthrough technology that is comprised of a unique and large cell population of astrocytes derived from human pluripotent stem cells. The cells are intended to support the survival of neurons in the central nervous system (CNS, brain and spinal cord). These neurons are damaged by ALS, due to the malfunctioning of the patient’s own astrocytes. This situation hampers and annuls the neuromuscular signaling, which negatively affects muscle activity and leads to eventual paralysis and death. In December 2020, Kadimastem announced the results of the first of its kind, Phase I/IIa clinical trial, in which healthy and functioning astrocyte cells (AstroRx®) were injected into the spinal fluid of 10 ALS patients. Data showed that AstroRx® has the potential to slow the progression of ALS, as indicated by a clinical score called ALSFRS-R. Kadimastem plans to test repeated doses every three months of AstroRx® to achieve a continuous delay of the disease. Based on data that the company has to date, the company estimates that approximately 3 years after the completion of the upcoming clinical trial and receiving marketing approval, the potential size of the ALS market could reach approximately 0.5 billion dollars annually [1]. “The patent announced today strengthens our intellectual property portfolio in the field of ALS and other neurodegenerative diseases. Not only is it a good sign that the patent was granted in the United States in advance of the next trial, but the timing also gives AstroRx® a clear advantage as it increases the strategic value of the product,” said Kadimastem CEO Asaf Shiloni. “We are currently engaged in intensive activities to submit the IND by the end of 2022 as well as preparations for the start of a Phase IIa clinical study in 2023 in the United States.” Kadimastem Chief Scientist Professor Michel Revel said, “The ALS program is progressing well. The company’s broad patent portfolio was strengthened today, and we are on track to begin the much anticipated clinical trial of AstroRx® within months. I am excited to see our original vision come to fruition. The goal is to improve improve the treatment of ALS patients.” [1] https://www.hopkinsmedicine.org/neurology_neurosurgery/centers_clinics/als/conditions/als_amyotrophic_lateral_sclerosis.html. https://www.hopkinsmedicine.org/neurology_neurosurgery/centers_clinics/als/conditions/als_amyotrophic_lateral_sclerosis.html. Based on data from the aforementioned source (there are 30,000 ALS patients in the US, as well as 5,000 new cases of ALS that are diagnosed each year), and under the following assumptions: (1) gradual entry into the market after receiving approval for the product; (2) each cellular treatment in the US will cost the payer at least about 25,000 US dollars (based on the benchmark work performed by the company); (3) Each ALS patient in the US will require about 4 cellular treatments from the company in one year, that is, an annual cost of at least about 100,000 US dollars. The company’s assessments regarding the tests that will be performed as part of the clinical trial, regarding the size of the potential market activity for the company in the US, the completion of the clinical trial and the receipt of marketing approval, constitute forward-looking information, as defined in the Securities Law, 1968, which is based, among other things, on data that the company has as of the date of this report. It is clarified that such estimates may not materialize and/or materialize in a materially different manner from the above. About Kadimastem: Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the Company's lead product, is an astrocyte cell therapy in clinical development as a treatment for ALS. IsletRx is the Company's second product in development. IsletRx is comprised of functional pancreatic islet cells intended to treat patients with insulin dependent diabetes. IsletRx demonstrated safety and efficacy in a proof-of-concept preclinical study. Kadimastem was founded by Professor Michel Revel, CSO of the Company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). Forward Looking Statement: This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Contact Details Kadimastem Asaf Shiloni +972 73-797-1613 s.bazak@kadimastem.com Must Have Communications Marjie Hadad +1 917-790-1178 marjie@mhc-pr.com Company Website https://www.kadimastem.com/

August 09, 2022 07:00 AM Eastern Daylight Time

Image

Industrial Defender Appoints Jay Williams as Chief Executive Officer

Industrial Defender

Industrial Defender, a leader in OT cybersecurity technology, today announced that Jay Williams has been appointed Chief Executive Officer of Industrial Defender effective August 8, 2022. Williams is a highly regarded cybersecurity executive with 30 years’ experience in operational environments and industrial control systems and 25 years’ executive leadership experience. As CEO, Williams will leverage his industry expertise and passion for team building to lead Industrial Defender through its next phase of growth, opening and expanding go-to-market channels, scaling the sales and innovation functions, and strengthening relationships with key partners and customers around the world. Williams brings a vision to elevate Industrial Defender as an integral enabler of OT cybersecurity transformation. “Jay is a respected leader in the space, whose deep understanding of operational business drivers, relentless customer focus and strategic experience driving global growth will be invaluable assets to Industrial Defender,” said Joseph Roark, Operating Partner at Teleo Capital and Chairman of Industrial Defender. “We’re excited to have Jay as part of the executive team and look forward to working with him to further scale the business and solidify Industrial Defender’s position as the leader in OT cybersecurity.” “I am honored to have the opportunity to lead and nurture the amazing talent and technology at Industrial Defender. With almost two decades of successfully implementing OT cybersecurity solutions at scale, we will continue to invest in complete, cost competitive technology to meet the needs of the future,” said Williams. “We have some very exciting new solutions being launched in the coming months that will empower security teams with the programmatic technology necessary to manage their entire OT cyber transformation from beginning to end. Every organization deserves to be secure no matter their size or budget, and Industrial Defender is committed to providing companies of all sizes with a competitive solution to protect their critical infrastructure.” Williams’ impressive background includes roles creating and leading OT cybersecurity divisions at Ernst & Young, Veracity Networks, Parsons Corporation, and Siemens. He is also an associate of the ICS Village and member of the Cybersecurity Advisory Council for the Syracuse City School District, teaching the next generation of students the core concepts to understand, assess and protect information security systems. To learn more about Jay Williams, why he chose Industrial Defender, and where the future of OT cybersecurity is heading, connect with him in person during BlackHat and the Defcon ICS Village August 8-15, 2022 in Las Vegas, NV. About Industrial Defender Industrial Defender protects the world’s critical infrastructure from cyberattacks. As a leader in OT cybersecurity innovation, the company’s scalable platform is used by organizations around the world to empower security stakeholders with actionable data collected from their OT and IIoT infrastructure, enabling them to make informed risk management decisions and manage their OT cybersecurity program in a concise, single vendor dashboard. Learn more at www.industrialdefender.com. Contact Details Industrial Defender Erin Anderson +1 617-675-4206 eanderson@industrialdefender.com Company Website https://www.industrialdefender.com

August 08, 2022 09:15 AM Eastern Daylight Time

Learn More about Simply Better Brands Corp. from Benzinga

Simply Better Brands

Contact Details Simply Better Brands Investor Relations ir@simplybetterbrands.com Company Website http://www.simplybetterbrands.com

August 05, 2022 03:21 PM Eastern Daylight Time

Video

UNOS Extended Statement on the Senate Finance Committee Hearing on Organ Donation & Transplant

United Network for Organ Sharing

Yesterday, UNOS CEO Brian Shepard appeared before the Senate Committee on Finance to testify about the role of United Network for Organ Sharing (UNOS) and the organ donation and transplant community’s ongoing efforts to save lives and further improve the national system. We were disappointed by the Senate Committee on Finance’s misunderstanding of the role UNOS has been assigned by the government within the nation’s organ donation and transplant system. To clarify some of the confusion, here are the facts about what we do: As required in the Health and Human Services (HHS) Organ Procurement and Transplantation Network (OPTN) contract, UNOS utilizes confidential peer-review, a highly effective process in use across the healthcare system, to promote hospital and OPO quality. Meanwhile, the Centers for Medicare and Medicaid Services (CMS) holds oversight authority, including OPO certification and decertification. These roles are distinct, specified and critical to the system. The IT system designed, operated and maintained by UNOS is highly effective, safe and secure, fending off more than three million hacker attempts per day. The U.S. Digital Service (USDS), which released a negative report on our IT infrastructure, didn’t come on-site to review it. However, The Health Resources and Services Administration (HRSA) routinely conducts on-site audits of the system, and has never found any of the purported deficiencies outlined by USDS. OPOs determine the best, safest way to transport donor organs. Transplant hospitals and OPOs coordinate between each other to ensure safe and timely transport and UNOS only becomes involved if contacted by one of these bodies. Though it is outside the scope of the HHS contract, UNOS responded to community needs by developing a GPS tracking tool that a quarter of OPOs now utilize. We were also very concerned that the Committee did not reference the National Academies of Sciences, Engineering and Mathematics (NASEM) yesterday, even though their important report, which was commissioned by Congress, includes many recommendations that our community is already undertaking and applauded UNOS’ approach to increasing equity through a new organ allocation framework. We remain dedicated to addressing these misperceptions and are looking forward to working with Congress to further improve. The U.S. organ donation and transplantation system is the most successful in the world and will soon exceed one million transplants in its history. Each represents a patient whose life was transformed. UNOS is proud of the community we have helped build and looks forward to continuing working together to serve all patients who rely on us. About UNOS United Network for Organ Sharing (UNOS) is the mission-driven non-profit serving as the nation’s transplant system under contract with the federal government. We lead the network of transplant hospitals, organ procurement organizations, and thousands of volunteers who are dedicated to honoring the gifts of life entrusted to us and to making lifesaving transplants possible for patients in need. Working together, we leverage data and advances in science and technology to continuously strengthen the system, increase the number of organs recovered and the number of transplants performed, and ensure patients across the nation have equitable access to transplant. Contact Details United Network for Organ Sharing Eric Steigleder +1 804-782-4730 eric.steigleder@unos.org Company Website https://unos.org

August 04, 2022 05:50 PM Eastern Daylight Time

UNOS Statement on the Senate Finance Committee Hearing Organ Donation & Transplant

United Network for Organ Sharing

Yesterday UNOS CEO Brian Shepard appeared before the Senate Committee on Finance to testify about the role of United Network for Organ Sharing (UNOS) and the organ donation and transplant community’s ongoing efforts to save lives and further improve the national system. We were surprised and disappointed by the Senate Committee on Finance’s misunderstanding of the role UNOS has been assigned by the government within the nation’s organ donation and transplant system. This includes the confidential peer-review process, which ensures ongoing improvement and is widely used across the U.S. healthcare setting. Still, we remain dedicated to working with Congress to improve the system, which saves more lives every year. We are proud to serve all patients who rely on us to accomplish this lifesaving work every day. The U.S. organ donation and transplantation system is the most successful in the world and will soon exceed one million transplants in its history. Each of those numbers represents a patient whose life was transformed, and we look forward to continue building upon these efforts with the community in the coming years. UNOS is proud of the network we have built together, serving all patients who rely on us to accomplish this lifesaving work. United Network for Organ Sharing (UNOS) is the mission-driven non-profit serving as the nation’s transplant system under contract with the federal government. We lead the network of transplant hospitals, organ procurement organizations, and thousands of volunteers who are dedicated to honoring the gifts of life entrusted to us and to making lifesaving transplants possible for patients in need. Working together, we leverage data and advances in science and technology to continuously strengthen the system, increase the number of organs recovered and the number of transplants performed, and ensure patients across the nation have equitable access to transplant. Contact Details United Network for Organ Sharing Eric Steigleder +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

August 04, 2022 04:08 PM Eastern Daylight Time

This Is How Often You Should Change Your Insurance Plans

Benzinga

As you move through life, your wants, needs and long-term goals will change with your lifestyle. Often, that means your insurance requirements evolve, too. Knowing when to change insurance carriers or plans ensures your coverage stays in line with your busy life. Here are a few important considerations when you need to shop for insurance. How Often Should You Change Your Insurance Plans? As a general rule, it’s wise to review your insurance plans: Every 6-12 months or once per coverage period Anytime your insurer hikes premium costs or slashes benefits When you experience a major event that impacts your coverage needs, like: Moving to a new house or region Making a major purchase (vehicles, fine jewelry) A birth or death in the immediate family Any of these reasons is enough to change insurance plans or carriers. Updating your coverage to match your needs (and your budget) ensures you protect the people and possessions you value most. But while cash is king, getting a good deal isn’t everything – the content of your policy matters, too. Sometimes, it’s worth paying a little more for your peace of mind. Benzinga explores a few potential reasons to change insurance carriers. You Can Find Cheaper Rates Elsewhere Regularly shopping for insurance helps you sniff out the carriers that offer better rates or discounts. Compare offers from at least three to five companies to ensure you’re getting the best deal on coverage. You’ve Recently Moved You may need to change insurance carriers when you move, especially if the move impacts your rates or coverage. Not all insurers operate in all regions – and even if yours does, your rates may rise based on location. For instance, you may pay higher auto insurance premiums in more populated areas. You Experience a Qualifying Event or Lifestyle Change Generally, you should reevaluate your coverage anytime you experience a “qualifying event” or major milestone like: Getting married or divorced Adding your teenager to your auto insurance Having or adopting a baby Retirement Whether you need more coverage, less coverage or a more affordable policy, consider such events an opportunity to evaluate and change insurance plans or carriers to fit your new lifestyle. Your Insurance Carrier Changes its Terms Maybe it’s not you who changes but your insurer. Carriers periodically update their geographic policies, prices, coverage offerings and accepted service providers. While the company may suggest alternatives, there’s no guarantee a replacement will suit your needs. You might as well take that opportunity to shop for insurance on your own. Your Provider Stops Accepting Insurance Health insurance is particularly finicky, with providers, insurers and in-network hospitals in flux. Maybe your doctor stops accepting Medicare insurance – or your Medicare plan stops paying for your doctor. Either way, you’ll have to switch insurance plans, doctors or both. Poor Customer Service or Claims Experiences When you’re paying your premiums, your insurance company is happy to take your money. But when you actually need to make a claim, you may find that it is reluctant to pay out. If you have to go through a major hassle to make a claim, receive your funds or just get a call back, it’s time to reconsider your carrier. Which Insurance Plans Should Change Regularly? You should review and compare insurance at least once a year, regardless of the type of policy. But some plans may need to change more – or less – frequently. Homeowners Shopping for homeowner’s insurance at least once a year ensures you don’t miss a better deal elsewhere. You may also change insurance carriers when your rates increase or you move to a new city. Making expensive renovations or purchases that require enhanced coverage also provides opportunities to change insurance plans. Auto Car insurance policies may not last a full year; some offer six-month plans. Either way, it’s wise to re-shop your auto insurance before every renewal, as car insurance rates famously fluctuate on a dime. Time, location, your driving history and even accidents that aren’t your fault can impact your individual premiums. Health Health insurance is a bit unique because many insurers limit plan switches or sign-ups to their annual open enrollment period. However, special exceptions exist for “qualifying life events” like marriage and divorce, having children, losing work coverage or moving to a new zip code. Life Life insurance pays out when the policyholder dies. Because it’s designed to pay for end-of-life expenses, lost income and housing costs, it’s crucial to buy enough coverage to secure your family’s future. On top of your annual evaluation, consider whether other life events impact your coverage needs, like: Your age and relationship status Having a baby Buying a home You might need to switch if your rates rise or you need higher coverage amounts. You may also want to switch to a different type of policy, such as moving from whole to permanent life insurance). Business Business insurance is a must for business owners to cover property damage, liability and business interruption costs. Because business needs are change, you may need to shop for insurance more than once a year. For instance, when you hire more employees, move to a new office or release new products, it’s probably time to increase your coverage or change insurance carriers. Compare Insurance Companies If you’re ready to shop for insurance plans, Benzinga has the insights you need to make an informed decision, from pet insurance to vision insurance. Frequently Asked Questions How frequently can you change car insurance? You can change car insurance as often as you need. You may have to pay a cancellation fee if you leave your current carrier in the middle of a policy. When should you switch insurance companies? You should consider switching insurance companies at least once a year to ensure you’re getting the best rates and coverage. You should actually make the switch when you can get better value elsewhere. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 04, 2022 02:58 PM Eastern Daylight Time

What You Need to Know About This Rare Chronic Autoimmune Disease

YourUpdateTV

Less than 150,000 people in the US suffer from IgA Nephropathy, a rare chronic autoimmune disease that affects the kidneys. The rarity of this disease leaves patients and their families feeling isolated and unsupported. Recently Andrew Udell, North America President at Calliditas Therapeutics and Judy Akin an IgA Nephropathy Patient and Advocate conducted a satellite media tour to talk about IgAN and available resources to diagnose it and treat. IgA nephropathy, sometimes referred to as IgAN, is a chronic autoimmune disease and is a leading cause of end-stage kidney disease with more than half of IgAN patients progressing to require dialysis or kidney transplant within 20 years of initial diagnosis. Although this disease affects kidneys and often results in kidney disease, it actually originates outside of the kidneys and it thought to start in the gut. Similar to other chronic autoimmune diseases, the burden of IgA nephropathy is significant. Only 130,000-150,000 people in the United States suffer from this disease, so patients and their families are often left feeling like they are living on an island with nowhere to turn to for support. Thankfully changes are happening. Both advocacy groups and biopharmaceutical companies are working towards providing support, education, and finding new treatments for this complicated disease. Whether you’ve just been diagnosed with IgA nephropathy (IgAN) or you’ve been living with the disease for many years, there are available resources to support you. IgAN Connect can help you understand IgAN, approaches to management, and ways to help you live with this chronic autoimmune disease. IgAN Connect also provides helpful information and resources you may need today or in the future. For more information and resources related to IgAN go to iganconnect.com. It is also always recommended that individuals living with IgA nephropathy, or their loved ones, speak directly with their doctor and engage with the numerous advocacy groups that exist to provide support. --------------------------- About Andy Udell As President, North America at Calliditas Therapeutics, Andrew Udell has more than 20 years of commercial experience in the pharmaceutical industry. Before joining Calliditas, Andrew worked as Vice President of North America Commercial at NeuroDerm. Andrew began his career in the pharmaceutical industry in various sales and marketing positions, including being responsible for a multi-functional team for a multi-billion franchise. About Judy Judy is an IgA nephropathy advocate. After her diagnosis with the rare disease in 2019, she began to share about her experiences through a written blog and on the social media platform TikTok. Judy has around 4000 followers on her TikTok account. Most of them are people living with various forms of chronic illness. A lot of her videos focus on the chronic pain and kidney disease that so often results from IgA nephropathy as well as the lifestyle choices she makes to help manage her disease. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

August 04, 2022 11:00 AM Eastern Daylight Time

Healthcare